You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Genuity, formerly known as WuXi NextCode, will sequence, analyze, and harmonize samples from Vanderbilt's biobank to inform biomarker and drug discovery.
Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.
M2Gen has seen its research database grow substantially, but now the firm must make the data useful across its clinical, pharma, and MDx partners.
The company will apply its single-cell RNA-seq analytics technology to three distinct cohorts in pursuit of new drug targets for inflammatory bowel disease.
The bioinformatics vendor is customizing a multiomics health data platform to help pancreatic cancer researchers pursue new therapeutic targets.
The firms are targeting a compatible offering for single-cell gene expression screens following CRISPR-based editing, with applications in drug discovery.
British bioinformatics firm PrecisionLife has mined the UK Biobank to identify genetic risk factors for late-stage COVID-19 patients developing sepsis.
Regeneron will sequence and annotate 450,000 exomes and pair the data with UCHealth patient records to advance drug discovery and precision medicine.
The firm's single-cell T cell receptor profiling method was published this month as part of a study to develop reusable antigen reactivity screens.
Investigators worldwide are sharing data to search for features in the human genome that might contribute to COVID-19 susceptibility or progression.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.